Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

IMVT

Immunovant Inc

Apr 13 • 01:34PM ET

24.93

+0.43 1.78 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA REGN VRTX BMRN CRSP SRPT NTLA RARE EDIT ARCT

| Held by: VTI XBI VB IWM VXF VBR IWO IBB VBK VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.68	Insider Own	58.71%	Shs Outstand	203.32M	Perf Week	0.18%
Market Cap	5.08B	Forward P/E	-	EPS next Y	-2.58	Insider Trans	16.08%	Shs Float	84.04M	Perf Month	-0.22%
Enterprise Value	4.08B	PEG	-	EPS next Q	-0.60	Inst Own	52.61%	Short Float	21.93%	Perf Quarter	-4.21%
Income	-464.20M	P/S	-	EPS this Y	4.03%	Inst Trans	5.74%	Short Ratio	13.67	Perf Half Y	42.65%
Sales	0.00M	P/B	5.14	EPS next Y	1.57%	ROA	-63.01%	Short Interest	18.43M	Perf YTD	-1.91%
Book/sh	4.85	P/C	5.10	EPS next 5Y	2.35%	ROE	-69.35%	52W High	29.25 -14.75%	Perf Year	69.86%
Cash/sh	4.89	P/FCF	-	EPS past 3/5Y	-24.09% -12.18%	ROIC	-47.07%	52W Low	13.36 86.64%	Perf 3Y	62.34%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.40% 5.00%	Perf 5Y	61.08%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-2.53%	Oper. Margin	-	ATR (14)	1.26	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.74	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.70	Recom	1.56
Dividend Gr. 3/5Y	- -	Current Ratio	15.74	EPS Q/Q	19.41%	SMA20	1.78%	Beta	0.68	Target Price	40.12
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-2.63%	Rel Volume	0.36	Prev Close	24.50
Employees	362	LT Debt/Eq	0.00	Earnings	Feb 06 BMO	SMA200	16.25%	Avg Volume	1.35M	Price	24.93
IPO	Jun 21, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.49% -	Trades		Volume	310,995	Change	1.78%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-20-26	Initiated	Bernstein	Mkt Perform	$28
Jan-06-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$50
Oct-14-25	Initiated	Truist	Hold	$16
Jul-10-25	Resumed	Goldman	Neutral	$18
Mar-03-25	Initiated	Jefferies	Hold	$20
Jan-03-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Oct-10-24	Resumed	Raymond James	Outperform	$36
Oct-09-24	Reiterated	Oppenheimer	Outperform	$47 → $53
Mar-28-24	Initiated	Oppenheimer	Outperform	$50
Mar-13-24	Initiated	Goldman	Buy	$50
Feb-20-24	Initiated	JP Morgan	Overweight	$51
Feb-15-24	Initiated	Wolfe Research	Outperform	$55
Dec-12-23	Initiated	Deutsche Bank	Buy	$50
Oct-13-23	Upgrade	UBS	Neutral → Buy	$18 → $55
Sep-26-23	Upgrade	Raymond James	Mkt Perform → Outperform	$40
May-01-23	Initiated	BofA Securities	Buy	$26
Apr-25-23	Initiated	Citigroup	Buy	$28
Mar-31-23	Initiated	Piper Sandler	Overweight	$28
Mar-30-23	Initiated	Stifel	Buy	$28
Feb-15-23	Initiated	Cantor Fitzgerald	Overweight	$30

Show Previous Ratings

Apr-02-26 08:20AM	Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM (BioPharma Dive)
07:00AM	Immunovant shares plunge after phase 3 trials fails to meet primary endpoint (Investing.com)
05:00AM	Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) (GlobeNewswire)
Mar-05-26 12:37PM	Immunovant Stock Surges 17% in 3 Months: What's Driving It? (Zacks)
Mar-04-26 02:30AM	Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update (Insider Monkey)
09:45AM	Loading…
Feb-19-26 09:45AM	Indivior Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-17-26 10:05AM	Arcutis Biotherapeutics to Report Q4 Earnings: What's in the Cards? (Zacks)
09:48AM	Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-09-26 11:42AM	IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus (Zacks)
Feb-06-26 10:10AM	Immunovant Q3 Earnings Call Highlights (MarketBeat) +12.43%
07:00AM	Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 (GlobeNewswire)
Feb-02-26 09:55AM	Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know (Zacks)
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-23-26 05:25PM	Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 (GlobeNewswire)
Jan-15-26 09:55AM	How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39% (Zacks)
10:11AM	Loading…
Jan-12-26 10:11AM	Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling (Insider Monkey)
Dec-17-25 09:45AM	Share Offerings Prompt Huge Insider Buying in These 3 Biotechs (24/7 Wall St.)
Dec-15-25 04:28PM	Argenx Flops, As Viridian Celebrates, On Surprise Setback For Vyvgart Powerhouse (Investor's Business Daily)
Dec-11-25 01:29AM	Immunovant Announces Pricing of $550 Million Common Stock Financing (GlobeNewswire) +5.31%
Dec-10-25 11:30AM	Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Nov-29-25 01:29PM	Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings (Insider Monkey)
Nov-11-25 12:52PM	Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus (Zacks)
Nov-10-25 07:00AM	Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 (GlobeNewswire)
Oct-31-25 10:03AM	Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results (Insider Monkey)
Oct-27-25 04:10PM	Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 (GlobeNewswire) +13.15%
Oct-08-25 12:57AM	JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37 (Insider Monkey)
Sep-30-25 04:00AM	Where is Immunovant (IMVT) Heading According to Analysts? (Insider Monkey)
Sep-10-25 11:30AM	Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-04-25 11:06AM	IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results (Zacks)
Sep-03-25 06:17PM	Why Immunovant Stock Blasted Higher Today (Motley Fool) +10.82%
12:57PM	Loading…
12:57PM	Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients (GlobeNewswire)
Aug-12-25 10:26AM	Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
Aug-11-25 07:00AM	Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 (GlobeNewswire)
Jul-16-25 12:00PM	All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy (Zacks)
09:55AM	Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High? (Zacks)
09:38AM	Goldman Sachs Resumes Coverage of Immunovant (IMVT) with a Hold Rating (Insider Monkey)
Jul-06-25 04:15AM	LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT (Insider Monkey)
Jun-02-25 12:00PM	Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-30-25 08:59AM	IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus (Zacks)
May-29-25 07:00AM	Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 (GlobeNewswire) +5.60%
May-09-25 09:02AM	Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back? (Insider Monkey)
Apr-22-25 06:00AM	Akeso claims another PD-1/VEGF win; FDA requests more data from Novavax (BioPharma Dive)
Apr-21-25 04:08PM	Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug (Investor's Business Daily)
10:18AM	Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift (Investor's Business Daily)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjogren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sj gren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
Apr-08-25 10:05AM	Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires? (Insider Monkey) -7.51%
Mar-24-25 01:56PM	Argenx: The Magic May Be Already Priced In (SeekingAlpha)
Mar-21-25 12:17PM	Immunovant price target raised to $61 from $58 at Stifel (TipRanks)
Mar-20-25 12:30PM	Immunovants batoclimab shows impressive efficacy in MG, says H.C. Wainwright (TipRanks)
10:19AM	IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success (Zacks)
09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-19-25 05:07PM	Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (SeekingAlpha)
04:04PM	Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. (Investor's Business Daily)
01:12PM	Immunovant will not seek approval for MG therapy, despite hitting endpoints (Clinical Trials Arena)
12:39PM	Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data (Benzinga)
09:26AM	Roivant, Immunovant Succeed In Phase 3. But There's A Twist And Shares Tumbled. (Investor's Business Daily)
07:45AM	Immunovant claims study success for immune disease drug but holds off on submission (BioPharma Dive)
07:45AM	Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies (GlobeNewswire)
Mar-18-25 04:32PM	Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs (GlobeNewswire) -6.14%
Mar-05-25 07:13PM	Immunovant, Inc. (IMVT): Among The Stocks With At Least $30 Million In Insider Spending Recently (Insider Monkey) +5.03%
Mar-04-25 04:50PM	Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity (Investor's Business Daily)
Feb-23-25 01:33PM	Immunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-22-25 12:53AM	Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now? (Insider Monkey)
Feb-19-25 04:49PM	Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently (Insider Monkey)
Feb-12-25 10:00AM	Roivant Sciences price target lowered to $12 from $13 at BofA (TipRanks)
09:35AM	Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Feb-10-25 11:57PM	Q3 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Feb-06-25 06:30AM	Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 (GlobeNewswire) -9.55%
Jan-30-25 05:03PM	Heres Why Immunovant, Inc. (IMVT) Will Double in 2025 (Insider Monkey)
Jan-17-25 11:10AM	Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-16-25 08:45AM	Roivant Sciences buys Immunovant Inc. shares and repurchases its own stock for $336.9 million each (GuruFocus.com)
Jan-13-25 08:00AM	Immunovant Announces $450 Million Private Placement (GlobeNewswire)
Dec-20-24 07:20AM	Immunovant price target lowered to $45 from $47 at Wells Fargo (TipRanks)
Nov-21-24 05:31PM	Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
Nov-13-24 03:05AM	Q2 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Nov-07-24 06:30AM	Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 (GlobeNewswire)
Oct-29-24 06:30AM	Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting (GlobeNewswire)
Oct-01-24 09:58AM	Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip? (Insider Monkey)
Sep-30-24 11:12AM	Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy? (Insider Monkey)
Sep-09-24 12:54PM	What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? (Benzinga) -7.61%
09:13AM	Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses (Pharmaceutical Technology)
07:00AM	Roivant Provides Update on Graves' Disease Development Program (GlobeNewswire)
03:55AM	Immunovant Provides Update on Graves' Disease Development Program (GlobeNewswire)
Sep-05-24 11:31AM	Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report? (Zacks) +9.55%
06:30AM	Immunovant to Host Graves' Disease Program Update on September 9, 2024 (GlobeNewswire)
Aug-09-24 12:20AM	Q1 2025 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Aug-06-24 04:05PM	Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024 (GlobeNewswire)
Jun-28-24 11:30AM	Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound? (Zacks)
May-31-24 08:04AM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript (Insider Monkey)
02:26AM	Q4 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
May-30-24 04:02PM	After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay (Investor's Business Daily) -10.69%
11:29AM	Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus (Zacks)
07:22AM	Immunovant changes up plans for closely watched autoimmune drugs (BioPharma Dive)
05:53AM	Immunovant shunts next-gen FcRn drug ahead of batoclimab in race to rival Vyvgart (FierceBiotech.com)
May-29-24 09:53PM	IMVT Stock Earnings: Immunovant Misses EPS for Q4 2024 (InvestorPlace)
04:06PM	Biohaven Tumbles After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump (Investor's Business Daily)
04:01PM	Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 (GlobeNewswire)
10:17AM	Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump (Investor's Business Daily)
May-27-24 06:28PM	Institutional Investors are Betting on Roivant Sciences (NASDAQ:ROIV) (Insider Monkey)

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Van Tuyl Christopher	Chief Legal Officer	Apr 08 '26	Sale	24.83	5,165	128,247	183,231	Apr 10 04:05 PM
Gloria Melanie	Chief Operating Officer	Apr 08 '26	Sale	24.83	8,722	216,567	245,222	Apr 10 04:03 PM
Stout Jay S	Chief Technology Officer	Apr 08 '26	Sale	24.83	10,132	251,578	254,439	Apr 10 04:02 PM
Venker Eric	Chief Executive Officer	Apr 01 '26	Option Exercise	14.46	368,750	5,332,125	368,750	Apr 03 04:33 PM
Venker Eric	Chief Executive Officer	Apr 02 '26	Sale	24.10	14,229	342,854	19,561	Apr 03 04:33 PM
Van Tuyl Christopher	Chief Legal Officer	Mar 18 '26	Sale	24.97	2,877	71,839	147,053	Mar 20 04:11 PM
Gloria Melanie	Chief Operating Officer	Feb 25 '26	Sale	27.85	3,238	90,184	170,273	Feb 27 04:07 PM
MICHAEL GEFFNER	Officer	Feb 10 '26	Proposed Sale	26.77	5,800	155,237		Feb 10 05:16 PM
Stout Jay S	Chief Technology Officer	Jan 21 '26	Sale	26.03	1,977	51,461	197,634	Jan 23 04:21 PM
Stout Jay S	Chief Technology Officer	Jan 07 '26	Sale	26.53	1,203	31,914	199,611	Jan 09 04:03 PM
Van Tuyl Christopher	Chief Legal Officer	Dec 18 '25	Sale	26.91	10,813	290,943	149,930	Dec 19 04:05 PM
Roivant Sciences Ltd.	Director	Dec 12 '25	Buy	21.00	16,666,666	349,999,986	113,317,007	Dec 12 05:17 PM
Fromkin Andrew J.	Director	Dec 01 '25	Sale	23.25	22,249	517,189	85,852	Dec 03 06:14 PM
Hughes Douglas J.	Director	Dec 01 '25	Sale	23.24	15,000	348,665	120,773	Dec 03 06:14 PM
ANDREW J FROMKIN	Director	Dec 01 '25	Proposed Sale	24.15	22,249	537,313		Dec 01 04:35 PM
DOUGLAS HUGHES	Director	Dec 01 '25	Proposed Sale	24.15	15,000	362,250		Dec 01 04:34 PM
MICHAEL GEFFNER	Officer	Nov 26 '25	Proposed Sale	23.70	50,000	1,185,045		Nov 26 05:07 PM
MICHAEL GEFFNER	Officer	Nov 25 '25	Proposed Sale	23.38	103,897	2,428,804		Nov 25 07:16 PM
Gloria Melanie	Chief Operating Officer	Nov 20 '25	Sale	23.62	12,626	298,237	173,511	Nov 21 04:24 PM
Geffner Michael	Chief Medical Officer	Oct 22 '25	Sale	19.03	2,595	49,383	217,958	Oct 24 04:38 PM
Stout Jay S	Chief Technology Officer	Oct 22 '25	Sale	19.03	2,520	47,956	200,814	Oct 24 04:36 PM
Geffner Michael	Chief Medical Officer	Oct 08 '25	Sale	16.30	1,272	20,734	220,553	Oct 10 04:03 PM
Stout Jay S	Chief Technology Officer	Oct 08 '25	Sale	16.30	1,585	25,836	203,334	Oct 10 04:01 PM
Stout Jay S	Chief Technology Officer	Jul 23 '25	Sale	18.15	2,805	50,911	204,919	Jul 25 05:11 PM
Geffner Michael	Chief Medical Officer	Jul 23 '25	Sale	18.15	2,385	43,288	221,825	Jul 25 05:10 PM
Geffner Michael	Chief Medical Officer	Jul 09 '25	Sale	17.24	1,160	19,998	224,210	Jul 11 04:15 PM
Stout Jay S	Chief Technology Officer	Jul 09 '25	Sale	17.24	1,519	26,188	207,724	Jul 11 04:13 PM
WILLIAM MACIAS	Officer	Jun 25 '25	Proposed Sale	15.83	30,000	474,861		Jun 25 04:02 PM
WILLIAM MACIAS	Officer	Jun 13 '25	Proposed Sale	15.57	50,000	778,490		Jun 13 05:34 PM
WILLIAM MACIAS	Officer	Jun 03 '25	Proposed Sale	15.61	80,000	1,248,616		Jun 03 05:42 PM
GEORGE V MIGAUSKY	Former Director	May 21 '25	Proposed Sale	14.58	21,812	318,047		May 21 04:24 PM
GEORGE V MIGAUSKY	Former Director	May 19 '25	Proposed Sale	14.58	28,188	410,908		May 19 04:40 PM
Stout Jay S	Chief Technology Officer	Apr 23 '25	Sale	14.79	1,925	28,471	209,243	Apr 25 04:17 PM
Geffner Michael	Chief Medical Officer	Apr 23 '25	Sale	14.79	2,349	34,742	225,370	Apr 25 04:15 PM
Barnett Eva Renee	Chief Financial Officer	Apr 16 '25	Sale	14.89	2,993	44,566	396,774	Apr 17 04:08 PM
Salzmann Peter	Chief Executive Officer	Apr 16 '25	Sale	14.89	8,321	123,900	1,178,191	Apr 17 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMVT

Immunovant Inc

Upgrade your Finviz experience